Disease Burden of MASH/MASLD Among People With Obesity in China, Japan, and EU5
Author(s)
Maria Choufany, PhD1, Amanda Woo, PhD2, Neeyor Bose, PhD3, Nikoletta Sternbach, BA4.
1Oracle Life Science, Paris, France, 2Oracle Life Sciences Singapore, Singapore, Singapore, 3Oracle Life Science Singapore, Singapore, Singapore, 4Oracle Life Science, Austin, TX, USA.
1Oracle Life Science, Paris, France, 2Oracle Life Sciences Singapore, Singapore, Singapore, 3Oracle Life Science Singapore, Singapore, Singapore, 4Oracle Life Science, Austin, TX, USA.
OBJECTIVES: Obesity and its related complications, including fatty liver disease (FLD), metabolic dysfunction-associated steatohepatitis (MASH), and the recently defined metabolic dysfunction-associated steatotic liver disease (MASLD), represent growing global public health concerns. This study aims to assess the burden of FLD in China, Japan and the 5EU (France, Germany, Italy, Spain, and the United Kingdom).
METHODS: Data from the National Health and Wellness Survey, an internet-based, cross-sectional survey of adults (≥18 years) in China, EU and Japan were used to evaluate patients diagnosed with MASH/MASLD, those at risk, and those never experienced MASH/MASLD and not at risk. The comparison of socio-demographic characteristics, Quality of Life outcomes (QoL), work productivity, and healthcare resource use (HCRU) across patient groups and regions were reported descriptively.
RESULTS: Patients diagnosed with MASH/MASLD and those at risk reported higher levels of moderate-to-severe depression (PHQ-9 ≥10) (China: 26.18-29.96% vs. 20.93%; 5EU: 36.51-50.81% vs. 20.67%; Japan: 32.12-29.32% vs. 14.75%), anxiety (GAD-7 ≥10) (China: 15.21-17.56% vs. 9.81%; 5EU: 25.39-39.72% vs. 13.84%; Japan: 21.17-23.64% vs. 10.13%), total work productivity impairment (China: 31.73-34.23% vs. 20.19%; 5EU: 38.17-55.12% vs. 22.31%; Japan: 37.11-37.53% vs. 20.36%), and total activity impairment (China: 24.99-27.07% vs. 17.26%; 5EU: 43.43-47.27% vs. 25.00%; Japan: 37.96-35.86% vs. 21.12%) than those never experienced and not at risk. Patients in the 5EU had the highest scores for all the measures compared to those in Japan and China.
Patients with MASH/MASLD had more GP visits, hospitalizations, and ER visits in the past six months than those never experienced and not at risk. Higher HCRU was observed in the 5EU, followed by Japan and China.
CONCLUSIONS: Patients diagnosed with MASH/MASLD present a significant burden on quality of life, reduced work productivity, and increased healthcare resource utilization. This highlights the need for targeted and comprehensive disease management of MASH/MASLD globally.
METHODS: Data from the National Health and Wellness Survey, an internet-based, cross-sectional survey of adults (≥18 years) in China, EU and Japan were used to evaluate patients diagnosed with MASH/MASLD, those at risk, and those never experienced MASH/MASLD and not at risk. The comparison of socio-demographic characteristics, Quality of Life outcomes (QoL), work productivity, and healthcare resource use (HCRU) across patient groups and regions were reported descriptively.
RESULTS: Patients diagnosed with MASH/MASLD and those at risk reported higher levels of moderate-to-severe depression (PHQ-9 ≥10) (China: 26.18-29.96% vs. 20.93%; 5EU: 36.51-50.81% vs. 20.67%; Japan: 32.12-29.32% vs. 14.75%), anxiety (GAD-7 ≥10) (China: 15.21-17.56% vs. 9.81%; 5EU: 25.39-39.72% vs. 13.84%; Japan: 21.17-23.64% vs. 10.13%), total work productivity impairment (China: 31.73-34.23% vs. 20.19%; 5EU: 38.17-55.12% vs. 22.31%; Japan: 37.11-37.53% vs. 20.36%), and total activity impairment (China: 24.99-27.07% vs. 17.26%; 5EU: 43.43-47.27% vs. 25.00%; Japan: 37.96-35.86% vs. 21.12%) than those never experienced and not at risk. Patients in the 5EU had the highest scores for all the measures compared to those in Japan and China.
Patients with MASH/MASLD had more GP visits, hospitalizations, and ER visits in the past six months than those never experienced and not at risk. Higher HCRU was observed in the 5EU, followed by Japan and China.
CONCLUSIONS: Patients diagnosed with MASH/MASLD present a significant burden on quality of life, reduced work productivity, and increased healthcare resource utilization. This highlights the need for targeted and comprehensive disease management of MASH/MASLD globally.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH63
Topic
Epidemiology & Public Health, Patient-Centered Research
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Mental Health (including addition), Urinary/Kidney Disorders